Whitehawk Therapeutics Inc (WHWK) Investor Relations Documents

Whitehawk Therapeutics Inc (WHWK) investor relations documents from the company's IR site: 1 presentation, 31 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

Whitehawk Therapeutics Corporate Presentation August 2026: Whitehawk is a clinical-stage biotech developing an ADC platform with $190M in cash, targeting 1H 2027 clinical data for lead assets HWK-007 and HWK-016.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releasePress release
2026-08-06Press releaseWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
2026-08-05PresentationWhitehawk Therapeutics Corporate Presentation August 2026
2026-07-07Press releasePress release
2026-07-07Press releaseBiocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
2026-06-23Press releasePress release
2026-06-21Press releasePress release
2026-06-17Press releasePress release
2026-06-15Press releasePress release
2026-06-15Press releasePress release
2026-05-30Press releasePress release
2026-05-30Press releaseWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target fo
2026-05-28Press releasePress release
2026-05-28Press releaseWhitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
2026-05-21Press releasePress release
2026-05-21Press releaseWhitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
2026-05-20Press releasePress release
2026-05-15Press releasePress release
2026-05-15Press releaseWhitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
2026-05-13Press releasePress release
2026-05-13Press releaseWhitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
2026-05-07Press releasePress release
2026-05-07Press releaseWhitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
2026-04-19Press releasePress release
2026-04-19Press releaseWhitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AAC
2026-04-16Press releaseWhitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
2026-04-10Press releaseWhitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target f
2026-03-17Press releaseWhitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (A
2026-03-12Press releaseWhitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
2026-02-26Press releaseWhitehawk Therapeutics to Participate in Upcoming Investor Conferences
2026-02-18Press releaseWhitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-01-08Press releaseWhitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-01
DocumentWhitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
DocumentWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
DocumentWhitehawk Reports First Quarter 2025 Financial Results and Recent Highlights

WHWK overview · WHWK earnings · WHWK financials · WHWK KPIs · WHWK ownership · WHWK peers · WHWK filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.